Atlantic Financial

Atlantic Healthcare is a specialist pharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal (GI) diseases and other inflammatory conditions. The company's lead candidate, Alicaforsen, is an antisense oligonucleotide that targets ICAM-1 to treat inflammatory disorders, with a primary focus on pouchitis, for which it has received Orphan Drug designation and is in Phase 3 development. Atlantic Healthcare also explores the use of Alicaforsen in ulcerative colitis and other forms of inflammatory bowel disease (IBD). Headquartered in the UK with offices in the US, the company leverages its expertise in GI health to address significant unmet medical needs.